APA (7th ed.) Citation

FCA, d. M., VKT, S., CR, D., N, H., FA, K., & RMR, B. (2025). A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 27(6), 2679. https://doi.org/10.1007/s12094-024-03772-2

Chicago Style (17th ed.) Citation

FCA, de Moraes, Sano VKT, Dantas CR, Hoffmeister N, Kelly FA, and Burbano RMR. "A Systematic Review and Meta-analysis of Cardiovascular Disease Risk with Degarelix and GnRH Agonists in Prostate Cancer." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 27, no. 6 (2025): 2679. https://doi.org/10.1007/s12094-024-03772-2.

MLA (9th ed.) Citation

FCA, de Moraes, et al. "A Systematic Review and Meta-analysis of Cardiovascular Disease Risk with Degarelix and GnRH Agonists in Prostate Cancer." Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol. 27, no. 6, 2025, p. 2679, https://doi.org/10.1007/s12094-024-03772-2.